Cite
Mirza AS, Tandon A, Jenneman D, et al. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022;doi: 10.1016/j.jtct.2022.01.003.
Mirza, A. S., Tandon, A., Jenneman, D., Cao, S., Brimer, T., Kumar, A., Kidd, M., Khimani, F., Faramand, R., Mishra, A., Liu, H., Nishihori, T., Perez, L., Lazaryan, A., Bejanyan, N., Nieder, M., Pidala, J., & Elmariah, H. (2022). Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2022.01.003
Mirza, Abu-Sayeef, et al. "Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation." Transplantation and cellular therapy vol. (2022). doi: https://doi.org/10.1016/j.jtct.2022.01.003
Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jan 08; doi: 10.1016/j.jtct.2022.01.003. Epub 2022 Jan 08. PMID: 35017119.
Copy
Download .nbib